Angiorus tablets p / o 900 mg + 100mg, No. 30

Therapy for the symptoms of chronic venous diseases (elimination and relief of symptoms).

Therapy for symptoms of venous lymphatic insufficiency:

• pain;

• cramps of the lower extremities;

• feeling of heaviness and fullness in the legs;

• 'Tiredness' of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

• swelling of the lower extremities;

• trophic changes in the skin and subcutaneous tissue;

• venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Inside, during meals.

The recommended dose for venous-lymphatic insufficiency is 1 tablet per day, preferably in the morning during meals.

The duration of the course of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

The recommended dose for acute hemorrhoids is 3 tablets per day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1 tablet per day with meals.

Active ingredients: hesperidin - 100 mg, diosmin - 900 mg.

Excipients:
Core composition: hypromellose, lactose monohydrate, talc, colloidal silicon dioxide, magnesium stearate, sodium carboxymethyl starch, microcrystalline cellulose M 102.
Shell composition: yellow opadry II.
Composition of yellow opaque II: macrogol-4000 (polyethylene glycol-4000), titanium dioxide, talc, polyvinyl alcohol, iron oxide yellow dye.

Hypersensitivity to the active or auxiliary substances that make up the drug.

It is not recommended to take the drug for women during breastfeeding.

Rare hereditary diseases such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Trade name:

ANGIORUS

International non-proprietary or group name:

hesperidin + diosmin

Dosage form:

film-coated tablets

Composition for 1 tablet:

Active ingredients: hesperidin - 100 mg, diosmin - 900 mg.

Excipients:
Core composition: hypromellose, lactose monohydrate, talc, colloidal silicon dioxide, magnesium stearate, sodium carboxymethyl starch, microcrystalline cellulose M 102.
Shell composition: yellow opadry II.
Composition of yellow opaque II: macrogol-4000 (polyethylene glycol-4000), titanium dioxide, talc, polyvinyl alcohol, iron oxide yellow dye.

Description

Biconvex tablets of oval shape, film-coated, yellow-brown color. The appearance of a tablet on a break is from light yellow to grayish yellow.

Pharmacotherapeutic group:

venotonic and venoprotective agent.

ATX code:

C05CA53

Pharmacological properties

Pharmacodynamics

The drug is a combination of micronized diosmin and hesperidin substances. This combination has venotonic and angioprotective effects. Reduces the distensibility of veins and venous congestion, reduces capillary permeability and increases their resistance, improves microcirculation and lymph drainage. With systematic use, it reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.

Pharmacokinetics

The main excretion of the drug occurs through the intestines. The kidneys, on average, excrete about 14% of the taken amount of the drug. The half-life is 11 hours.

The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.

Indications for use

Therapy for the symptoms of chronic venous diseases (elimination and relief of symptoms).

Therapy for symptoms of venous lymphatic insufficiency:

• pain;

• cramps of the lower extremities;

• feeling of heaviness and fullness in the legs;

• 'Tiredness' of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

• swelling of the lower extremities;

• trophic changes in the skin and subcutaneous tissue;

• venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Contraindications

Hypersensitivity to the active or auxiliary substances that make up the drug.

It is not recommended to take the drug for women during breastfeeding.

Rare hereditary diseases such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Application during pregnancy and during breastfeeding

Pregnancy

Animal experiments did not reveal teratogenic effects. So far, there have been no reports of any side effects when using the drug by pregnant women.

Breastfeeding period

Due to the lack of data on the elimination of the drug in breast milk, it is not recommended to take the drug for women during breastfeeding.

Impact on reproductive function

Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.

Method of administration and dosage

Inside, during meals.

The recommended dose for venous-lymphatic insufficiency is 1 tablet per day, preferably in the morning during meals.

The duration of the course of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

The recommended dose for acute hemorrhoids is 3 tablets per day (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1 tablet per day with meals.

Side effect

The incidence of adverse reactions is presented in accordance with the WHO classification: very often (? 1/10), often (? 1/100, <1/10), infrequently (? 1/1000, <1/100), rarely (? 1 / 10000, <1/1000), very rare (<1/10000), frequency unknown (frequency cannot be estimated from available data).

From the side of the central nervous system: rarely - dizziness, headache, general malaise.

From the digestive system: often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; frequency unknown - abdominal pain.

Allergic reactions: rarely - skin rash, pruritus, urticaria; frequency unknown - isolated edema of the face, lips, eyelids. In exceptional cases, angioedema.

In the event of the above adverse reactions or adverse reactions that are not specified in these instructions for medical use of the medicinal product, you should consult a doctor.

Overdose

There are no data on overdose.

In case of drug overdose, seek medical attention immediately.

Interaction with other medicinal products

There are no data on interactions with other drugs.

The attending physician should be informed about all medications taken.

special instructions

Before using the drug, it is recommended to consult a doctor.

With an exacerbation of hemorrhoids, the appointment of the drug does not replace the specific treatment of other anal disorders. The duration of treatment should not exceed the time specified in the section 'Dosage and Administration'. In the event that the symptoms do not disappear after the recommended course of therapy, a proctological examination should be carried out and the therapy used should be reviewed.

In the presence of disorders of venous circulation, the maximum effect of treatment is provided by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings can help improve blood circulation.

If during the course of treatment your condition worsens or does not improve, see your doctor immediately.

Influence on the ability to drive vehicles, mechanisms

The drug does not affect the ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Release form

Film-coated tablets 100 mg + 900 mg.
On 5, 10, 15 tablets in blister strip packaging from a film of polyvinyl chloride and printed aluminum foil varnished.
On 20, 30, 60 tablets in polymer jars made of polypropylene, low pressure polyethylene.
Each can, 4, 6 blister packs of 5 tablets, 2, 3, 6 blister packs of 10 tablets or 2, 4 blister packs of 15 tablets with instructions for use are placed in a cardboard box.

Storage conditions

At a temperature not higher than 30 ? C.
Keep out of the reach of children.

Shelf life

2 years.
Do not use after the expiration date.

Vacation conditions

Available without a prescription.